Vera wins FDA accelerated approval for TRUTAKNA in primary IgA nephropathy based on 42% proteinuria cut in Phase 3 trial

Vera Therapeutics, Inc. Class A

Vera Therapeutics, Inc. Class A

VERA

0.00
  • Vera Therapeutics secured FDA accelerated approval for TRUTAKNA (atacicept-vymj) to reduce proteinuria in adults with primary IgA nephropathy.
  • ORIGIN 3 interim data showed a 42% proteinuria reduction versus placebo at 36 weeks, with a 46% drop from baseline (p<0.0001).
  • Approval rests on proteinuria; long-term kidney benefit remains unproven, with eGFR results from ORIGIN 3 expected in Q3 2026.
  • TRUTAKNA is dosed 150 mg subcutaneously once weekly via autoinjector, self-administered at home.
  • Most common adverse reactions were infections (32% vs 28%) and local administration reactions (30% vs 5%).


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vera Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607071237PRIMZONEFULLFEED9758319) on July 07, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.